Oral Bioavailability of Two Solid Formulations of GLPG0259.

Galapagos NV12 enrolled

Overview

The purpose of the study is to evaluate the relative bioavailability of two solid oral formulations of GLPG0259 administered after a meal.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

GLPG0259 fumarateDRUG

single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate

GLPG0259 free baseDRUG

single oral dose, GLPG0259, 50 mg solid formulation

Eligibility

Sex: MALEMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * healthy male, age 18-50 years * BMI between 18-30 kg/m², inclusive. Exclusion Criteria: * significantly abnormal platelet function or coagulopathy * smoking * drug or alcohol abuse

Locations (1)

SGS Stuivenberg

Antwerp, Belgium

Outcomes

Primary Outcomes

Bioavailability of two solid dosage formulations of GLPG0259

Time frame: up to 96 hours postdose

Secondary Outcomes

Safety and tolerability of GLPG0259

Time frame: up to 96 hours postdose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.